{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:06:43Z","timestamp":1790831203984,"version":"4.1.0"},"reference-count":87,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant mesothelioma (MM) is a very aggressive asbestos-related cancer, for which no therapy proves to be effective. We have recently shown that the oncolytic adenovirus dl922-947 had antitumor effects in MM cell lines and murine xenografts. Previous studies demonstrated that dl922-947-induced host cell cycle checkpoint deregulation and consequent DNA lesions associated with the virus efficacy. However, the cellular DNA damage response (DDR) can counteract this virus action. Therefore, we assessed whether AZD1775, an inhibitor of the G2\/M DNA damage checkpoint kinase WEE1, could enhance MM cell sensitivity to dl922-947. Through cell viability assays, we found that AZD1775 synergized with dl922-947 selectively in MM cell lines and increased dl922-947-induced cell death, which showed hallmarks of apoptosis (annexinV-positivity, caspase-dependency, BCL-XL decrease, chromatin condensation). Predictably, dl922-947 and\/or AZD1775 activated the DDR, as indicated by increased levels of three main DDR players: phosphorylated histone H2AX (\u03b3-H2AX), phospho-replication protein A (RPA)32, phospho-checkpoint kinase 1 (CHK1). Dl922-947 also increased inactive Tyr-15-phosphorylated cyclin-dependent kinase 1 (CDK1), a key WEE1 substrate, which is indicative of G2\/M checkpoint activation. This increase in phospho-CDK1 was effectively suppressed by AZD1775, thus suggesting that this compound could, indeed, abrogate the dl922-947-induced DNA damage checkpoint in MM cells. Overall, our data suggest that the dl922-947-AZD1775 combination could be a feasible strategy against MM.<\/jats:p>","DOI":"10.3390\/ijms21197333","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T08:35:57Z","timestamp":1601886957000},"page":"7333","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines"],"prefix":"10.3390","volume":"21","author":[{"given":"Carmelina Antonella","family":"Iannuzzi","sequence":"first","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Indovina","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"},{"name":"Institute for High Performance Computing and Networking, National Research Council of Italy (ICAR-CNR), I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-5844","authenticated-orcid":false,"given":"Iris Maria","family":"Forte","sequence":"additional","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Di Somma","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze Mediche Traslazionali, Universit\u00e0 di Napoli \u201cFederico II\u201d, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6193-2835","authenticated-orcid":false,"given":"Anna Maria","family":"Malfitano","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze Mediche Traslazionali, Universit\u00e0 di Napoli \u201cFederico II\u201d, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena, I-53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Portella","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze Mediche Traslazionali, Universit\u00e0 di Napoli \u201cFederico II\u201d, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-6801","authenticated-orcid":false,"given":"Francesca","family":"Pentimalli","sequence":"additional","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-016X","authenticated-orcid":false,"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"},{"name":"Department of Medical Biotechnologies, University of Siena, I-53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10937404.2016.1195322","article-title":"Environmental risk of mesothelioma in the United States: An emerging concern-epidemiological issues","volume":"19","author":"Baumann","year":"2016","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: Recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The Lancet Respiratory Medicine (2019). Pleural mesothelioma: Tackling a deadly cancer. Lancet Respir. Med., 7, 99.","DOI":"10.1016\/S2213-2600(19)30004-9"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., B\u00f6l\u00fckbas, S., Boyd, J., and Coolen, J. (2020). ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur. Respir. J., 55.","DOI":"10.1183\/13993003.00953-2019"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcancer.2019.09.014","article-title":"Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies","volume":"61","author":"Hinz","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword against Cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113986","DOI":"10.1016\/j.bcp.2020.113986","article-title":"Virotherapy: From single agents to combinatorial treatments","volume":"177","author":"Malfitano","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic Viral Therapy for Mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fonc.2019.00564","article-title":"The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth","volume":"9","author":"Iannuzzi","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/cgt.2011.45","article-title":"An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine","volume":"18","author":"Bhattacharyya","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/0008-5472.CAN-05-2691","article-title":"Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: Comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin","volume":"66","author":"Lockley","year":"2006","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1089\/hum.2009.181","article-title":"PED\/PEA-15 modulates coxsackievirus-adenovirus receptor expression and adenoviral infectivity via ERK-mediated signals in glioma cells","volume":"21","author":"Botta","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-08-0200","article-title":"Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947","volume":"14","author":"Libertini","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Malfitano, A.M., Somma, S.D., Prevete, N.G., and Portella, G. (2019). Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer. Cancers, 11.","DOI":"10.3390\/cancers11101532"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"key":"ref_19","unstructured":"Giordano, A., and Franco, R. (2019). Molecular markers of mesothelioma aiding in diagnostic challenges: The combined use of p16 and BAP1. Malignant Pleural Mesothelioma: A Guide for Clinicians, Academic Press."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2","article-title":"The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma","volume":"7","author":"Prins","year":"1998","journal-title":"Int. J. Cancer."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fonc.2017.00195","article-title":"Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer","volume":"7","author":"Howells","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-3-319-67577-0_11","article-title":"Oncolytic Virotherapy and the Tumor Microenvironment","volume":"1036","author":"Berkey","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.18632\/oncotarget.6430","article-title":"The oncolytic virus dl922-947 reduces IL-8\/CXCL8 and MCP-1\/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma","volume":"7","author":"Passaro","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1158\/0008-5472.CAN-08-0817","article-title":"Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis","volume":"68","author":"Connell","year":"2008","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molonc.2014.07.022","article-title":"PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma","volume":"9","author":"Passaro","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI43976","article-title":"Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells","volume":"121","author":"Connell","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1530\/ERC-13-0001","article-title":"Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells","volume":"20","author":"Passaro","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2018.1511700","article-title":"Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy","volume":"27","author":"Fu","year":"2018","journal-title":"Expert Opin. Investig. Drug"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Tang","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-19-3470","article-title":"Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)","volume":"26","author":"Cole","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11523-020-00701-5","article-title":"Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study","volume":"15","author":"Kato","year":"2020","journal-title":"Target. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","article-title":"A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/cbt.9.7.11276","article-title":"Targeting the checkpoint kinase WEE1: Selective sensitization of cancer cells to DNA-damaging drugs","volume":"9","author":"Indovina","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-18-3374","article-title":"Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition","volume":"80","author":"Liang","year":"2020","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e57894","DOI":"10.7554\/eLife.57894","article-title":"PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer","volume":"9","author":"Brunner","year":"2020","journal-title":"Elife"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/0008-5472.CAN-18-2480","article-title":"Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress","volume":"79","author":"Young","year":"2019","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-17-2805","article-title":"The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer","volume":"24","author":"Lallo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13046-018-0790-7","article-title":"Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint","volume":"37","author":"Lin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","article-title":"Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition","volume":"71","author":"Haynes","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/0008-5472.CAN-12-2669","article-title":"Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma","volume":"73","author":"Russell","year":"2013","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-014-0053-9","article-title":"CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells","volume":"7","author":"Qi","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.2013.093187","article-title":"CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo","volume":"99","author":"Chaudhuri","year":"2014","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ghelli Luserna Di Ror\u00e0, A., Bocconcelli, M., Ferrari, A., Terragna, C., Bruno, S., Imbrogno, E., Beeharry, N., Robustelli, V., Ghetti, M., and Napolitano, R. (2019). Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11111654"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Deneka, A.Y., Einarson, M.B., Bennett, J., Nikonova, A.S., Elmekawy, M., Zhou, Y., Lee, J.W., Burtness, B.A., and Golemis, E.A. (2020). Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers, 12.","DOI":"10.3390\/cancers12020306"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","article-title":"Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer","volume":"20","author":"Jin","year":"2018","journal-title":"Neoplasia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bcp.2019.04.022","article-title":"Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis","volume":"164","author":"Qi","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/cc.11.5.19519","article-title":"Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition","volume":"11","author":"Cozzi","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-018-0641-1","article-title":"Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia","volume":"11","author":"Beeharry","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41598-017-18900-y","article-title":"Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib","volume":"8","author":"Caiola","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1158\/1078-0432.CCR-18-0440","article-title":"Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"De Jong, M.R.W., Langendonk, M., Reitsma, B., Herbers, P., Nijland, M., Huls, G., van den Berg, A., Ammatuna, E., Visser, L., and van Meerten, T. (2019). WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage. Cancers, 11.","DOI":"10.3390\/cancers11111743"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/1078-0432.CCR-19-0775","article-title":"Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer","volume":"26","author":"Corella","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10120-019-00977-1","article-title":"Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors","volume":"23","author":"Liu","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijc.32515","article-title":"Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer","volume":"146","author":"Takashima","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_59","unstructured":"Hu, J., Wang, T., Xu, J., Wu, S., Wang, L., Su, H., Jiang, J., Yue, M., Wang, J., and Wang, D. (2020). WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia. Haematologica."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.16614","article-title":"The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma","volume":"191","author":"Liang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e1488359","DOI":"10.1080\/2162402X.2018.1488359","article-title":"WEE1 kinase inhibition reverses G2\/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy","volume":"7","author":"Sun","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e1638207","DOI":"10.1080\/2162402X.2019.1638207","article-title":"Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition","volume":"8","author":"Patel","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/1078-0432.CCR-19-1627","article-title":"Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy","volume":"26","author":"Hai","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4161\/cbt.27623","article-title":"Abrogating G(2)\/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma","volume":"15","author":"Indovina","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-19-0724","article-title":"CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/carcin\/bgq026","article-title":"Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy","volume":"31","author":"Varin","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1475-2867-12-45","article-title":"Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition","volume":"12","author":"Guertin","year":"2012","journal-title":"Cancer Cell Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.canlet.2014.10.015","article-title":"Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer","volume":"356","author":"Wang","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.18632\/oncotarget.6364","article-title":"A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase","volume":"7","author":"Sakurikar","year":"2016","journal-title":"Oncotarget"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.radonc.2016.11.017","article-title":"G2-checkpoint targeting and radiosensitization of HPV\/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1","volume":"122","author":"Busch","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1158\/0008-5472.CAN-17-3932","article-title":"Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine","volume":"78","author":"Koh","year":"2018","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/15384101.2019.1593649","article-title":"p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775","volume":"18","author":"Hauge","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/cr.2014.147","article-title":"RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response","volume":"25","author":"Zou","year":"2015","journal-title":"Cell Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Patil","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/sj.onc.1210977","article-title":"Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer","volume":"27","author":"Baird","year":"2008","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1038\/s41419-017-0110-8","article-title":"RIPK3 promotes adenovirus type 5 activity","volume":"8","author":"Weigert","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/cc.27546","article-title":"Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma","volume":"13","author":"Forte","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-09-0787","article-title":"Targeting the RB-pathway in cancer therapy","volume":"16","author":"Knudsen","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"17873","DOI":"10.18632\/oncotarget.4286","article-title":"RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy","volume":"6","author":"Indovina","year":"2015","journal-title":"Oncotarget"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bcp.2019.06.003","article-title":"Translating RB1 predictive value in clinical cancer therapy: Are we there yet?","volume":"166","author":"Indovina","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1038\/s41388-018-0214-3","article-title":"RBL2\/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines","volume":"37","author":"Pentimalli","year":"2018","journal-title":"Oncogene"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/onc.2011.286","article-title":"New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization","volume":"31","author":"Indovina","year":"2012","journal-title":"Oncogene"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"71660","DOI":"10.18632\/oncotarget.12311","article-title":"MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells","volume":"7","author":"Bridges","year":"2016","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"23891","DOI":"10.1073\/pnas.1915108116","article-title":"WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells","volume":"116","author":"Moiseeva","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"111720","DOI":"10.1016\/j.yexcr.2019.111720","article-title":"Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells","volume":"386","author":"Nojima","year":"2020","journal-title":"Exp. Cell Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-18-1620","article-title":"Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer","volume":"25","author":"Chung","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:16:26Z","timestamp":1760177786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,4]]},"references-count":87,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21197333"],"URL":"https:\/\/doi.org\/10.3390\/ijms21197333","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,4]]}}}